You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

immuno-chemotherapy

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)

Active, not recruiting
  • Biliary Tract Neoplasms
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 26, 2021

Immunotherapy, Analgesia, NSCLC Trial in Tianjin (neoadjuvant immunotherapy, Neoadjuvant chemo)

Recruiting
  • Immunotherapy
  • +3 more
  • neoadjuvant immunotherapy
  • Neoadjuvant chemotherapy
  • Tianjin, Tianjin, China
  • +2 more
Aug 23, 2022

NSCLC Patients Trial in Marseille (procedure, diagnostic test, other)

Recruiting
  • Non-small Cell Lung Cancer Patients
  • BIOPSY
  • +2 more
  • Marseille, France
    Assistance Pubique Hopitaux de Marseille
Sep 21, 2022

Assessing the Presence of CT-DNA in Lymphoma Associated HLH

Not yet recruiting
  • Lymphoma
  • Haemophagocytic Lymphohistiocytosis
    • (no location specified)
    Jan 25, 2023

    Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity

    Recruiting
    • Nasopharyngeal Carcinoma
    • Camrelizumab, gemcitabin, cisplatin
    • Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
    • Guangzhou, Guangdong, China
      Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
    Jun 19, 2022

    Anti-COVID-19 Humoral and Memory T Cell Responses in Various

    Active, not recruiting
    • Immune Response
    • blood collection
    • Paris, France
      Hôpital Robert Debré
    Sep 15, 2022

    Cancer, Solid Tumor, Colorectal Cancer Trial (biological, radiation, drug)

    Not yet recruiting
    • Cancer
    • +8 more
    • DK210 (EGFR)
    • +3 more
    • (no location specified)
    Jan 27, 2023

    Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade 3A Trial in Italy (OFATUMUMAB)

    Completed
    • Follicular Lymphoma, Grade 1
    • +2 more
    • Alessandria, AL, Italy
    • +26 more
    Jun 16, 2022

    NSCLC, NSCLC Trial in Switzerland (Durvalumab, Radiotherapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • NSCLC
    • Aarau, Switzerland
    • +12 more
    Oct 17, 2022

    Newly Diagnosed Glioblastoma Trial (Pembrolizumab)

    Not yet recruiting
    • Newly Diagnosed Glioblastoma
    • (no location specified)
    Feb 22, 2022

    Lung Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Placebo)

    Completed
    Has Results
    • Lung Cancer
    • Nivolumab
    • +2 more
    • Sacramento, California
    • +195 more
    Jan 25, 2022

    Advanced Solid Tumors, NSCLC Trial in Hackensack (BMS-986442, Nivolumab, Docetaxel)

    Not yet recruiting
    • Advanced Solid Tumors
    • Non-small Cell Lung Cancer
    • BMS-986442
    • +5 more
    • Hackensack, New Jersey
      John Theurer Cancer Center at Hackensack University Medical Cent
    Sep 14, 2022

    MSI-H Colorectal Cancer Trial (colorectal resection)

    Completed
    • MSI-H Colorectal Cancer
    • colorectal resection
    • (no location specified)
    May 22, 2023

    Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

    Not yet recruiting
    • Metastatic Pancreatic Cancer
    • Durvalumab
    • Rintatolimod
    • Rotterdam, Zuid-Holland, Netherlands
      Erasmus MC
    Jun 23, 2023

    NSCLC Stage III Trial in Paris, Milan, Barcelona (durvalumab plus platinum-based chemo (cisplatin or carboplatin plus

    Recruiting
    • Non-small Cell Lung Cancer Stage III
    • durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)
    • +2 more
    • Paris, France
    • +2 more
    May 30, 2022

    NSCLC, Non-Small-Cell Lung Carcinoma, Circulating Tumor DNA Trial (biological, drug, other)

    Withdrawn
    • Non-Small Cell Lung Cancer
    • +2 more
    • Nivolumab
    • +8 more
    • (no location specified)
    Mar 9, 2022

    Triple Negative Breast Cancer, Breast Cancer Trial in United States (Trilaciclib, Cylophosphamide, Doxorubicin)

    Active, not recruiting
    • Triple Negative Breast Cancer
    • Breast Cancer
    • Los Alamitos, California
    • +6 more
    Jan 25, 2023

    Urinary Bladder Tumors, Muscle-Invasive Bladder Cancer Trial in Worldwide (Nivolumab, Gemcitabine, Cisplatin)

    Active, not recruiting
    • Urinary Bladder Neoplasms
    • Muscle-Invasive Bladder Cancer
    • Nivolumab
    • +2 more
    • Tucson, Arizona
    • +172 more
    Jan 25, 2023

    Dyad's Perspectives on Treatment Decision, Financial and Family

    Recruiting
    • Breast Cancer
      • Taipei, Taiwan
        National Taiwan University Hospital
      Jun 15, 2023

      Breast Cancer, Renal Cell Carcinoma Trial in United States (IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel)

      Active, not recruiting
      • Breast Cancer
      • Renal Cell Carcinoma
      • IPI-549 (eganelisib)
      • +3 more
      • Chandler, Arizona
      • +23 more
      Apr 1, 2022

      SARS-CoV-2 Infection Trial in United States (Evusheld (tixagevimab+cilgavimab) IM or IV)

      Recruiting
      • SARS-CoV-2 Infection
      • Evusheld (tixagevimab+cilgavimab) IM or IV
      • Fountain Valley, California
      • +33 more
      Jun 24, 2022

      Malignant Pleural Mesothelioma Trial in Edegem, Ghent, Sint-Niklaas (Dendritic cell vaccination, Atezolizumab,

      Not yet recruiting
      • Malignant Pleural Mesothelioma
      • Dendritic cell vaccination
      • +2 more
      • Edegem, Antwerp, Belgium
      • +2 more
      Feb 28, 2023

      Cervical Cancer Trial in Worldwide (carboplatin, cisplatin, paclitaxel)

      Active, not recruiting
      • Cervical Cancer
      • Birmingham, Alabama
      • +124 more
      Nov 17, 2022

      Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced

      Recruiting
      • Gastric Cancer
      • Gastric Adenocarcinoma
      • Beijing, Beijing, China
        Beijing Cancer Hospital
      Apr 4, 2023

      Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I

      Recruiting
      • Clinical Stage 0 Gastric Cancer AJCC v8
      • +27 more
      • Houston, Texas
        M D Anderson Cancer Center
      Jul 5, 2022